Table 3

Area under the curve values for ROC curves of baseline versus delayed prognostication scores (listed left) for 30-day, 90-day and 180-day mortality, and poor functional outcome (modified Rankin Scale of 4–5) in all patients (placebo treated and DFO treated) meeting inclusion criteria

	Mortality (baseline vs delayed)			Poor functional outcome (baseline vs delayed)
	30-day	90-day	180-day	30-day	90-day	180-day
Original ICH score	0.73 vs 0.82 (0.002)	0.74 vs 0.82 (0.015)	0.74 vs 0.83 (0.005)	0.71 vs 0.74 (0.14)	0.74 vs 0.72 (0.34)	0.79 vs 0.77 (0.34)
Modified-ICH score	0.76 vs 0.83 (0.027)	0.76 vs 0.82 (0.080)	0.73 vs 0.80 (0.036)	0.71 vs 0.75 (0.033)	0.73 vs 0.73 (0.86)	0.77 vs 0.76 (0.78)
Max-ICH score	0.74 vs 0.83 (<0.000)	0.74 vs 0.83 (<0.000)	0.77 vs 0.84 (0.008)	0.77 vs 0.82 (0.011)	0.84 vs 0.82 (0.373)	0.86 vs 0.82 (0.13)
FUNC score	0.66 vs 0.75 (0.054)	0.66 vs 0.74 (0.058)	0.70 vs 0.77 (0.061)	0.63 vs 0.62 (0.39)	0.69 vs 0.65 (0.18)	0.68 vs 0.66 (0.43)

Statistical significance is highlighted using bold font. P values are represented in parentheses.
DFO, deferoxamine mesylate; ICH, intracerebral haemorrhage; ROC, receiver operating characteristic.